Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding
Others
Ratios

Viking Therapeutics (VKTX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $164.7 million.

  • Viking Therapeutics' Operating Expenses rose 25628.27% to $164.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $393.3 million, marking a year-over-year increase of 16062.77%. This contributed to the annual value of $393.3 million for FY2025, which is 16062.77% up from last year.
  • According to the latest figures from Q4 2025, Viking Therapeutics' Operating Expenses is $164.7 million, which was up 25628.27% from $98.6 million recorded in Q3 2025.
  • In the past 5 years, Viking Therapeutics' Operating Expenses registered a high of $164.7 million during Q4 2025, and its lowest value of $12.5 million during Q4 2021.
  • In the last 5 years, Viking Therapeutics' Operating Expenses had a median value of $25.5 million in 2023 and averaged $38.6 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 1104.21% in 2021, then skyrocketed by 25628.27% in 2025.
  • Over the past 5 years, Viking Therapeutics' Operating Expenses (Quarter) stood at $12.5 million in 2021, then surged by 62.13% to $20.3 million in 2022, then soared by 44.38% to $29.3 million in 2023, then skyrocketed by 57.89% to $46.2 million in 2024, then soared by 256.28% to $164.7 million in 2025.
  • Its last three reported values are $164.7 million in Q4 2025, $98.6 million for Q3 2025, and $74.6 million during Q2 2025.